Gilead Sciences Inc. (GILD)
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Gilead Sciences Remains A Buy After A 40% Rally
Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by rising demand for Biktarvy, Descovy, and Sunlenca. So, sales of Biktarvy, the flagship of Gilead's HIV franchise, amounted to $3.77 billion, an increase of 21.4% year-on-year.
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Gilead Sciences Inc. NASDAQ: GILD stock surged to a new 52-week high at $106.69 recently on its fourth quarter of 2024 earnings release. After being asleep for so many years, the stock has finally found interest again, hitting price levels not seen in a decade.
GILD or VRTX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
Here is how Gilead Sciences (GILD) and Natera (NTRA) have performed compared to their sector so far this year.
Calls of the Day: Gilead Sciences and Merck
The Investment Committee debate the Calls of the Day in two biotech names.
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive.
Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70.
Why Gilead Sciences Stock Is Jumping Today
Shares of Gilead Sciences (GILD 7.14%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial results following market close on Tuesday.
Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
